Impact of Obesity Interventions on Managed Care

June 1, 2016
Supplements and Featured Publications, Impact of Obesity Interventions on Managed Care, Volume 22, Issue 7 Suppl

Publishing Staff

Senior Vice President of Operations and Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager

Ida Delmendo

Clinical Projects Manager

Cindy Spielvogel

Project Manager

Jessica Toye

Proofreaders

Griselda Demassey

Maggie Shaw

Associate Editor

Jeanne Linke

Assistant Editor

Sarah Anwar

Clinical Editor

Michael R. Page, PharmD, RPh

Designer

Julianne Costello

Associate Publisher

Justin T. Gallagher

Director of Sales

Sara Belanger

National Account Managers

Gabrielle Consola

Michael Costella

Corporate

Chairman and CEO

Mike Hennessy, Sr

Vice Chairman

Jack Lepping

President

Mike Hennessy, Jr

Chief Operating Officer/CFO

Neil Glasser, CPA/CFE

President, Managed Markets, Pharmacy, and Rare Disease

Brian Haug

Executive Vice President and General Manager

John Maglione

Chief Creative Officer

Jeff Brown

Human Resources Director

Shari Lundenberg

President, Pharmacy Times Continuing Education

David Heckard

PARTICIPATING FACULTY

Caroline M. Apovian, MD, FACP, FACN

Director

Nutrition and Weight Management Center

Boston Medical Center

Professor of Medicine and Pediatrics

Boston University School of Medicine

Boston, Massachusetts

Scott Kahan, MD, MPH

Medical Director

Strategies to Overcome and Prevent (STOP) Obesity Alliance

George Washington University

Director

National Center for Weight and Wellness

Washington, DC

Kenneth L. Schaecher, MD, FACP, CPC

Medical Director

SelectHealth

Salt Lake City, Utah

Jill E. Allen, PharmD

Drug Information Consultant

Pin Oak Associates

Salt Lake City, Utah

Christine Sokoloski, MS

Medical Writer

Hillsborough, New Jersey

Jeannette Y. Wick, RPh, MBA, FASCP

Visiting Professor

University of Connecticut School of Pharmacy

Storrs, Connecticut

Editorial Support

Caroline M. Apovian, MD, FACP, FACN, has the following relevant financial relationships with commercial interests to disclose:

Consultant:

Amylin, Arena, EnteroMedics, Gelesis, Johnson and Johnson, Merck, Novo Nordisk, Nutrisystem, Orexigen, Sanofi-Aventis, Scientific Intake, Takeda, Zafgen

Research Funding:

Amylin, Aspire Bariatrics, the Dr. Robert C. and Veronica Atkins Foundation, GI Dynamics, Lilly, MetaProteomics, MYOS Corporation, Orexigen, Pfizer, Sanofi-Aventis

Stock:

Science Smart LLC

Scott Kahan, MD, MPH, has the following relevant financial relationships with commercial interests to

disclose:

Board Membership:

American Board of Obesity Medicine

Consultant:

Novo Nordisk, Orexigen, Takeda, Vivus

Kenneth L. Schaecher, MD, FACP, CPC, has no relevant financial relationships with commercial

interests to disclose.

Faculty Disclosures

  • Editorial Support Disclosures

Jill E. Allen, PharmD; Christine Sokoloski, MS; and Jeannette Wick, RPh, MBA, FASCP, have no

relevant financial relationships with commercial interests to disclose.

The American Journal of Managed Care

Publishing Staff—Jeff D. Prescott, PharmD, RPh; Ida Delmendo; and Cindy Spielvogel have no relevant

financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education

Planning Staff—Dave Heckard; Maryjo Dixon, RPh; Dipti Desai, PharmD, RPh; Beatriz Manzor Mitrzyk,

PharmD, BCPS; Donna Fausak; Nathalie Harden; and Tara DeLorenzo have no relevant financial

relationships with commercial interests to disclose.

Disclosure Policy

According to the disclosure policy of The American Journal of Managed Care and Pharmacy Times Continuing Education, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Disclosure of Unapproved/Off-Label Use

The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and

are advised to consult prescribing information for these products.

The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care, Pharmacy Times Continuing Education, or any of the companies that provided commercial support for this CE activity.